Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Journal of Pediatric Psychology|April 16, 2013
The relationships between fatigue, quality of life, and family impact among children with special health care needsI-Chan Huang, Mary Anderson, Pranav Gandhi, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 27, 2017
Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarinXue Song, Pranav Gandhi, Adrienne M Gilligan, et al.
Pain Management|November 19, 2025
Patient-centered outcomes in the acute treatment of migraine: a prospective, real-world, longitudinal survey study (UNIVERSE II) comparing migraine patients who switch from a prior triptan to another triptan or ubrogepantRichard B Lipton, Amit Bodhani, Xingyu Gao, et al.
Headache|March 25, 2024
Impact of headache frequency and preventive treatment failure on quality of life, disability, and direct and indirect costs among individuals with episodic migraine in the United StatesDavid W Dodick, Michael L Reed, Lulu Lee, et al.
Headache|September 2, 2025
Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timingRichard B Lipton, Jonathan Stokes, Christopher J Evans, et al.
Cephalalgia : an International Journal of Headache|November 19, 2024
Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene-related peptide monoclonal antibodiesJessica Ailani, Anjana Lalla, Rashmi B Halker Singh, et al.
The Journal of Headache and Pain|August 23, 2023
Impact of headache frequency and preventive medication failure on quality of life, functioning, and costs among individuals with migraine across several European countries: need for effective preventive treatmentDawn C Buse, Patricia Pozo-Rosich, Laure Dupont-Benjamin, et al.
Neurology|November 17, 2022
Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE TrialRichard B Lipton, Patricia Pozo-Rosich, Andrew M Blumenfeld, et al.
Headache|September 9, 2024
Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraineJessica Ailani, Pranav Gandhi, Anjana Lalla, et al.
Cephalalgia : an International Journal of Headache|August 28, 2023
Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trialRichard B Lipton, Rashmi B Halker Singh, Laszlo Mechtler, et al.
Pageof 3